ClinicalTrials.Veeva

Menu
M

MedDerm Associates | San Diego, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-04965842
Upadacitinib
Dupilumab
Guselkumab
CP-690,550
Secukinumab
Risankizumab
Ruxolitinib
Filgotinib
ASLAN004

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 24 total trials

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Enrolling
Plaque Psoriasis
Drug: Apremilast

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Biological: Lutikizumab
Drug: Placebo

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community...

Active, not recruiting
Psoriasis
Drug: Deucravacitinib
Other: Placebo

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

AbbVie logo
Pfizer logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
M
A
Bristol-Myers Squibb (BMS) logo
G
Gilead Sciences logo
Incyte logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems